Evidence map›Paper›PMID 31790363›Full record

ArticleAging2019

Glycolysis gene expression profilings screen for prognostic risk signature of hepatocellular carcinoma.

Longyang Jiang, Lan Zhao, Jia Bi, Qiutong Guan, Aoshuang Qi, Qian Wei, Miao He, Minjie Wei, Lin Zhao

Open access · greenAbstract read
In one paragraph

Article in Aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. CENPA-driven STMN1 Transcription Inhibits Ferroptosis in Hepatocellular Carcinoma.Journal of clinical and translational hepatology · 2023
    Article
  8. Article
  9. Review
  10. Biomedicines · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Longyang JiangDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang North New Area, Shenyang 110122, Liaoning, China.
Lan ZhaoDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang North New Area, Shenyang 110122, Liaoning, China.
Jia BiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang North New Area, Shenyang 110122, Liaoning, China.
Qiutong GuanDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang North New Area, Shenyang 110122, Liaoning, China.
Aoshuang QiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang North New Area, Shenyang 110122, Liaoning, China.
Qian WeiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang North New Area, Shenyang 110122, Liaoning, China.
Miao HeDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang North New Area, Shenyang 110122, Liaoning, China.
Minjie WeiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang North New Area, Shenyang 110122, Liaoning, China.
Lin ZhaoDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang North New Area, Shenyang 110122, Liaoning, China.
China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic changes are the markers of cancer and have attracted wide attention in recent years. One of the main metabolic features of tumor cells is the high level of glycolysis, even if there is oxygen. The transformation and preference of metabolic pathways is usually regulated by specific gene expression. The aim of this study is to develop a glycolysis-related risk signature as a biomarker via four common cancer types. Only hepatocellular carcinoma was shown the strong relationship with glycolysis. The mRNA sequencing and chip data of hepatocellular carcinoma, breast invasive carcinoma, renal clear cell carcinoma, colorectal adenocarcinoma were included in the study. Gene set enrichment analysis was performed, profiling three glycolysis-related gene sets, it revealed genes associated with the biological process. Univariate and multivariate Cox proportional regression models were used to screen out prognostic-related gene signature. We identified six mRNAs (DPYSL4, HOMER1, ABCB6, CENPA, CDK1, STMN1) significantly associated with overall survival in the Cox proportional regression model for hepatocellular carcinoma. Based on this gene signature, we were able to divide patients into high-risk and low-risk subgroups. Multivariate Cox regression analysis showed that prognostic power of this six gene signature is independent of clinical variables. Further, we validated this data in our own 55 paired hepatocellular carcinoma and adjacent tissues. The results showed that these proteins were highly expressed in hepatocellular carcinoma tissues compared with adjacent tissue. The survival time of high-risk group was significantly shorter than that of low-risk group, indicating that high-risk group had poor prognosis. We calculated the correlation coefficients between six proteins and found that these six proteins were independent of each other. In conclusions, we developed a glycolysis-related gene signature that could predict survival in hepatocellular carcinoma patients. Our findings provide novel insight to the mechanisms of glycolysis and it is useful for identifying patients with hepatocellular carcinoma with poor prognoses.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularGene Expression ProfilingGlycolysisHumansLiver NeoplasmsPrognosisRisk FactorsBiomarkers, Tumorglycolysishepatocellular carcinomaprognosticrisksignature

Identifiers

PMID31790363
PMCPMC6932884
OpenAlexW2993308521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.